Life Science Nation Newsletter  |  September 4, 2014  |  Issue 78

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
In This Issue

RESI Panel Announcement: Family Offices Investing Direct

Five Reasons Why Family Offices Invest in Life Science Companies 

From the Road: LSN Fundraising Boot Camp


Life Science Investor Mandates (Aug. 27 - Sept. 3)
Seeking Devices, Services Providers and Later Stage Therapeutics
Seeking Clinical Stage Oncology Opportunities

Looking Opportunistically in Life Sciences

LSN Videos
RESI Partnering Platform
[Book] The Life Science Executive's Fundraising Manifesto
Quick Links

RESI Panel Announcement: Family Offices Investing Direct
By Michael Quigley, Director of Research, LSN


In recent years, family offices and private wealth investors have become an increasingly important pool of capital for fundraising entrepreneurs in the life science space. Unlike angels or high-net-worth individuals who generally have up to $100 million in capital and opportunistic investment mandates, family offices and private wealth groups represent families and individuals who have $100 million to $1 billion or more in total assets and who use a more institutional investment approach....

Moderated by Bill Brah, Founder & Executive Director of UMASS Venture Development Center, the panel includes the following speakers:
  • John Nelson, Managing Director, Genrich Inc.
  • Melissa Krauth, Principal, Claria Bioscience
  • Meredith Fisher, Director and Partner Investments, Private Investment Office
  • Chris DeSouza, Director, Broadview Ventures
  • Alejandra Paredones, CEO and Founder, BSI Capital Group
  • Todd Holmes, Director, Gurnet Point Capital
Five Reasons Why Family Offices Invest in Life Science Companies

By Lucy Parkinson, Senior Research Manager, LSN


At LSN, we meet many life science entrepreneurs seeking capital, and they are generally aware of some of the options they have for funding. In fact, they may already be approaching venture capital firms, the licensing arms of pharmaceutical companies, or nonprofits that give grants in their field. Yet many entrepreneurs are surprised to learn that family offices are investing in the early stage life science space-and in significant numbers.


Why have so many family offices moved into this space? There are many motivations, but in talking to family offices, we've found that the following five reasons are the most common:


Sophisticated Investment Strategies. As institutional investors with significant assets under management, family offices use a variety of strategies to conserve and grow their wealth....


From the Road: LSN Fundraising Boot Camp

By Jack Fuller, Director of Business Development, LSN

LSN has developed the Life Science Fundraising Boot Camp, a training workshop that we present around the world. I recently had the opportunity to travel to a number of life science organizations throughout the southern and western U.S. to teach entrepreneurs about the changing investor landscape. After traveling to four cities in as many days, and presenting to companies with assets and technologies in various stages from discovery through clinical, I was struck by the deep need for information about tactical skills for fundraising. A VC can pontificate about the current regulatory environment and speak in broad terms about developing a strategic plan for a company; however, virtually no one is willing to tell the life science community that fundraising can require making up to 30 phone calls a day for 9 to 18 months. 

If you're looking at that number in disbelief, ask the most successful fundraising executive you know what it took to get funding...

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668


follow us: Follow us on Twitter View our profile on LinkedIn  

Michael Quigley, Director of Research, LSN
Nono Hu, Senior Manager, Branding & Messaging, LSN